Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Update

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) saw a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 18,900 shares, an increase of 9.2% from the January 15th total of 17,300 shares. Based on an average daily volume of 43,200 shares, the short-interest ratio is presently 0.4 days. Currently, 0.7% of the company’s shares are short sold.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Kiora Pharmaceuticals stock. ADAR1 Capital Management LLC raised its position in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) by 1.9% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 200,221 shares of the company’s stock after buying an additional 3,670 shares during the period. ADAR1 Capital Management LLC owned about 6.67% of Kiora Pharmaceuticals worth $661,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 76.97% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Kiora Pharmaceuticals in a research note on Tuesday, November 12th.

Kiora Pharmaceuticals Price Performance

KPRX traded up $0.02 on Monday, hitting $3.62. 24,728 shares of the company were exchanged, compared to its average volume of 35,204. The firm has a fifty day simple moving average of $3.59 and a two-hundred day simple moving average of $3.56. Kiora Pharmaceuticals has a 12 month low of $3.00 and a 12 month high of $6.75.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.